Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation.

Kok CH, Watkins DB, Leclercq T, D'Andrea RJ, Hughes TP, White DL.

Leukemia. 2013 Jun;27(6):1427-30. doi: 10.1038/leu.2013.47. Epub 2013 Feb 15. No abstract available.

PMID:
23411466
2.

Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.

Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.

Eur J Haematol. 2004 Apr;72(4):231-8.

PMID:
15089759
3.

Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1.

Soliera AR, Mariani SA, Audia A, Lidonnici MR, Addya S, Ferrari-Amorotti G, Cattelani S, Manzotti G, Fragliasso V, Peterson L, Perini G, Holyoake TL, Calabretta B.

Leukemia. 2012 Jul;26(7):1555-63. doi: 10.1038/leu.2012.19. Epub 2012 Jan 30.

PMID:
22285998
4.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood. 2005 Apr 15;105(8):3303-11. Epub 2004 Dec 30.

5.

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.

Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R.

Mol Cancer Ther. 2007 Apr;6(4):1400-5.

6.

Bcr/Abl activates transcription of the Bcl-X gene through STAT5.

Gesbert F, Griffin JD.

Blood. 2000 Sep 15;96(6):2269-76.

7.
8.

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.

Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.

Oncogene. 2002 Dec 12;21(57):8804-16.

9.

The growth factor independence-1 (Gfi1) is overexpressed in chronic myelogenous leukemia.

Huang M, Hu Z, Chang W, Ou D, Zhou J, Zhang Y.

Acta Haematol. 2010;123(1):1-5. doi: 10.1159/000253856. Epub 2009 Nov 2.

PMID:
19887785
10.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

11.

Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.

Fernandez-Luna JL.

Apoptosis. 2000 Oct;5(4):315-8. Review.

PMID:
11227211
12.

Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.

Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL.

Oncogene. 1996 Jul 18;13(2):247-54.

PMID:
8710363
13.
14.

Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.

Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J.

Blood. 1996 Aug 1;88(3):809-16.

15.

STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells.

de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L.

Mol Cell Biol Res Commun. 2000 May;3(5):299-305.

PMID:
10964754
16.
18.

Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.

Retnakumari AP, Hanumanthu PL, Malarvizhi GL, Prabhu R, Sidharthan N, Thampi MV, Menon D, Mony U, Menon K, Keechilat P, Nair S, Koyakutty M.

Mol Pharm. 2012 Nov 5;9(11):3062-78. doi: 10.1021/mp300172e. Epub 2012 Oct 5.

PMID:
22971013
20.
Items per page

Supplemental Content

Write to the Help Desk